Logo

GeneGo Licenses GVK's Compound DB for Use with Pathway Software

Jun 04, 2007
NEW YORK (GenomeWeb News) - GVK Biosciences of Hyderabad, India, has licensed its Medicinal Chemistry Database to the software and data-services company GeneGo, the companies said today.
 
GeneGo plans to integrate the MedChem database into its Metacore and MetaDrug platforms.
 
GeneGo's vice president of business development, Julie Bryant, said the agreement marks the first time the company has licensed third-party content for use in its platforms.
 
Pharmaceutical researchers use GeneGo's MetaCore 4.3 to target, identify, and validate biomarkers for diseases and toxicity. They use its MetaDrug 4.2 to help predict human metabolism, toxicity, and the effects of small molecule compounds.
 
GVK's Medicinal Chemistry Database contains more than 650,000 compounds accompanied by biological and pharmacological information, according to the company.
 
Financial terms of the agreement were not released.

Filed under

Informatics
Breaking News
The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.